These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9727125)

  • 1. A new form of heparin is changing treatment of thrombotic disorders.
    Capriotti T
    Medsurg Nurs; 1998 Apr; 7(2):106-9, 98. PubMed ID: 9727125
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations?
    Zakarija A; Bennett CL
    Arch Intern Med; 2005 Apr; 165(7):722-3. PubMed ID: 15824289
    [No Abstract]   [Full Text] [Related]  

  • 4. [Thrombophilia and thrombogenic orthopedic surgery].
    Grouille D; Orsel I; Schneider L; Ben Rhaiem M
    Cah Anesthesiol; 1995; 43(1):89-90. PubMed ID: 7671066
    [No Abstract]   [Full Text] [Related]  

  • 5. Venous thrombosis prophylaxis with low-molecular-weight heparin in hip and knee arthroplasty.
    Colwell CW
    Instr Course Lect; 2002; 51():487-9. PubMed ID: 12064138
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful management of acute portal vein thrombosis by low molecular weight heparin and oral anticoagulation.
    Hegenbarth K; Fickert P; Aschauer M; Horina JH; Stauber RE; Trauner M
    Am J Gastroenterol; 2002 Jun; 97(6):1567-8. PubMed ID: 12094892
    [No Abstract]   [Full Text] [Related]  

  • 7. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

  • 8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute thrombotic disorders.
    Kuntz JG; Cheesman JD; Powers RD
    Am J Emerg Med; 2006 Jul; 24(4):460-7. PubMed ID: 16787806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty.
    Colwell CW; Hardwick ME
    Clin Orthop Relat Res; 2006 Nov; 452():181-5. PubMed ID: 17016231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 12. [Indications and clinical application of thrombosis prophylaxis. I].
    Mittelkötter U; Reith HB; Thiede A
    Zentralbl Chir; 2000; 125(7):W49-52. PubMed ID: 10960979
    [No Abstract]   [Full Text] [Related]  

  • 13. Hirudin versus heparin and low-molecular-weight heparin: and the winner is..
    Hull RD; Pineo GF; Raskob GE
    J Lab Clin Med; 1998 Sep; 132(3):171-4. PubMed ID: 9735921
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)].
    Martyin T; Jakucs J; Iványi J; Kis E; Varga I; Mellár E
    Orv Hetil; 1998 Dec; 139(51):3065-9. PubMed ID: 9914726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of low-molecular-weight heparin in cardiovascular medicine.
    Hirsh J; Bates SM
    Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of thrombosis during pregnancy.
    Inbal A
    Isr Med Assoc J; 2002 Oct; 4(10):813-4. PubMed ID: 12389348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.